Nuveen Q4 2025 13F Holdings and Activity Report

I. Institutional Overview

Nuveen, the investment management arm of TIAA, stands as one of the most formidable institutional forces in the global financial landscape. As of the fourth quarter of 2025, the institution’s 13F filing reveals a reported portfolio value of a staggering $380,883,057,575 ($380.88B) . This scale places Nuveen in an elite tier of asset managers, where its every move signals broader market trends and reflects the collective wisdom of thousands of underlying investment mandates. To understand Nuveen is to understand the "ballast" of the American equity market; its portfolio is not merely a collection of bets but a comprehensive map of institutional confidence across the entire economic spectrum.

The institution’s psychological state this quarter appears to be one of "Prudent Rebalancing." Despite the massive AUM, Nuveen is not stagnant. The data shows a clear intent to harvest profits from the most overheated segments of the "Magnificent Seven"—specifically Meta Platforms and NVIDIA—while rotating that liquidity into defensive growth (Healthcare) and internal structural vehicles (Nushares ETFs). This suggests a management team that is wary of "concentration risk" at the top of the S&P 500 and is actively seeking to "internalize" its investment logic by moving assets into proprietary ETF structures.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

II. Sector Allocation Analysis

While Technology remains the largest slice of the pie, the internal movements within the sectors suggest a subtle rotation. The 9.58% allocation to Healthcare is particularly noteworthy. In Q4 2025, Nuveen made significant additions to Eli Lilly (LLY), Johnson & Johnson (JNJ), and Regeneron (REGN). This move into Healthcare signals a "flight to quality." Healthcare companies often provide "defensive growth"—they possess the pricing power and essential demand to weather economic slowdowns, while also offering upside through biotech innovation (e.g., GLP-1 drugs and immunology).

Nuveen’s sector layout implies a "Cautiously Optimistic" view of the US economy. The heavy weight in Consumer Discretionary (11.09%) shows confidence in the American consumer’s resilience. Meanwhile, the robust Industrial (8.82%) and Financial (12.77%) holdings suggest that the "Real Economy" is functioning well. Nuveen is not hiding in cash or deep defensive sectors like Utilities; it is staying "in the game" but is increasingly mindful of the valuations in the mega-cap tech space, as evidenced by its systematic trimming of the largest portfolio components.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

III. Top 10 Holdings Deep Dive

The Top 10 holdings of Nuveen represent the "ballast stones" of a $380B ship. These positions account for a significant portion of the total portfolio value and reflect the institution's core conviction.

Nuveen’s Top 10 is heavily skewed toward Large-Cap Growth . The top 10 stocks alone account for roughly 34% of the entire $380B portfolio . This high concentration at the top is balanced by the 3,196 stocks that make up the remaining 66%. This "Barbell" approach allows Nuveen to capture the explosive returns of the tech giants while using a massive tail of diversified stocks to mitigate the impact of any single company’s failure. The investment philosophy here is clear: "Own the winners, but don't let them own you."

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

IV. Major Buys/Additions

The buy list is heavily clustered in Healthcare (REGN, JNJ, ABBV) and Proprietary ETFs . This reveals a clear trend: "De-risking through Diversification." By adding to three major healthcare names simultaneously, Nuveen is building a "defensive wall." These companies are characterized by high dividends, massive cash flows, and low sensitivity to the economic cycle. This is a "clustering" behavior that suggests Nuveen is preparing for a market where "beta" (market-wide growth) is harder to come by, and "alpha" must be found in specific sector tailwinds like the aging population and biotech breakthroughs.

Where did the money come from? The $4B+ deployed into Nushares ETFs and the $1B+ into Healthcare and Software was largely funded by the $2B+ profit-taking in Meta Platforms and the systematic trims in NVDA, MSFT, and AMZN. This is a perfect example of "Inventory Reallocation." Nuveen is not necessarily bringing "new" money into the market; it is recycling capital from the "winners of yesterday" (Mega-cap AI) into the "stability of tomorrow" (Healthcare and Internal ETFs). This rotation reduces the portfolio's "Maximum Drawdown" risk while maintaining exposure to long-term growth themes.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

V. Major Sells and Exits

The overall quality of Nuveen’s exits this quarter is "Proactive and Disciplined." They are not "panic selling" distressed assets; instead, they are selling their "winners" (META, NVDA, COST, NOW). This is the hallmark of a sophisticated institutional manager. By selling when things are "good," they ensure they have the cash to buy when things are "bad." The exit of 68 total positions (including small names like Kellanova and Weibo) shows a commitment to "Portfolio Slimming" —removing the "tail" of the portfolio to focus on higher-conviction ideas.

The primary risk signal from Nuveen’s selling is "Valuation Fatigue." When a $380B fund trims its largest and most successful positions by 3% to 21%, it is a warning that the "easy money" in the AI and mega-cap trade has been made. Nuveen is signaling that the market may be entering a phase where "stock selection" and "sector rotation" will be more important than simply "owning the index." Their retreat from Meta and Costco, in particular, suggests a wariness of stocks that have "decoupled" from their historical valuation norms.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

VI. Investment Insights and Risk Warnings

The core logic chain can be summarized as follows: 1. Harvesting the Winners : Nuveen recognized that the "Magnificent Seven" (specifically Meta and NVIDIA) reached valuation levels that posed a concentration risk to a $380B portfolio. They systematically extracted billions in liquidity from these names. 2. Internalizing the Structure : Instead of keeping that liquidity in cash or third-party funds, Nuveen moved it into its own Nushares ETFs (NXUS, NHYB) . This move captures the management fees internally and allows for a more controlled, systematic exposure to international and fixed-income markets. 3. Rotating to "Defensive Growth" : The institution redeployed its "alpha" capital into Healthcare (REGN, JNJ, ABBV) and Quality Software (INTU) . This suggests a belief that the next phase of the market will reward companies with "essential" products and strong balance sheets over those with purely "speculative" growth stories. 4. The Apple Exception : By adding to Apple (AAPL) while selling other tech giants, Nuveen is signaling that it views Apple as the "safest" of the mega-caps, likely due to its massive buybacks and "consumer staple" status.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

Sources and limitations

This report uses public U.S. Securities and Exchange Commission Form 13F disclosures and structured data maintained by 13F Hub. A 13F filing is a quarter-end snapshot of reportable long positions, is normally published with a delay, and does not disclose every short position, cash balance, bond, derivative, or non-U.S. asset.

Narrative content is prepared from the same-period SEC disclosure and 13F Hub structured data, then checked before publication. This material is for research and education, not personalized investment advice.